Elevated expression levels of syndecan-1 have been reported in breast cancer, pancreatic cancer, and squamous cell carcinoma of the lung, whereas increased levels of syndecan-2 have been observed in melanoma and colon cancer [65]. Here, SDC2 is linked to colonic neoplasm.